New Zealand markets close in 6 hours 3 minutes

Spruce Biosciences, Inc. (SPRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.2550-0.0550 (-2.38%)
At close: 04:00PM EDT
2.3000 +0.04 (+2.00%)
After hours: 05:28PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.3100
Open2.2700
Bid2.2500 x 3000
Ask2.3000 x 800
Day's range2.2400 - 2.2980
52-week range0.9550 - 3.5700
Volume89,908
Avg. volume1,605,950
Market cap89.627M
Beta (5Y monthly)2.33
PE ratio (TTM)N/A
EPS (TTM)-1.9800
Earnings date09 May 2023 - 15 May 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.00
  • Business Wire

    Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates

    SOUTH SAN FRANCISCO, Calif., March 16, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2022 and provided corporate updates.

  • Business Wire

    Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., February 28, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 2:40 PM ET.

  • Business Wire

    Spruce Biosciences Announces $53.6 Million Private Placement Financing

    SOUTH SAN FRANCISCO, Calif., February 09, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $53.6 million, before deducting offering expenses. The private placement inclu